The pharmaceutical industry's demand for high-quality intermediates fuels advancements in drug manufacturing. Clidinium Bromide, identified by its CAS Number 3485-62-9, is a prominent pharmaceutical intermediate recognized for its anticholinergic properties. This article examines its chemical characteristics and its significant role in producing essential medications.

Clidinium Bromide is presented as a white crystalline solid, a physical state that facilitates its handling and integration into various chemical processes. Its molecular formula is C22H26BrNO3, and its molecular weight is 432.35 g/mol. These structural and compositional details are critical for its application in pharmaceutical synthesis. The compound's anticholinergic activity is key to its therapeutic value, enabling it to act as an antispasmodic agent.

In the pharmaceutical realm, Clidinium Bromide serves as a crucial raw material, most notably in the formulation of antispasmodic drugs. These medications are widely used to manage gastrointestinal disorders, including Irritable Bowel Syndrome (IBS) and peptic ulcers. By inhibiting the action of acetylcholine, Clidinium Bromide helps to reduce muscle spasms in the digestive tract and decrease gastric acid secretion, thereby alleviating patient discomfort.

The synthesis of Clidinium Bromide demands rigorous quality control to ensure a minimum purity of 97%, a standard essential for pharmaceutical intermediates. The reliable sourcing of this Clidinium Bromide for IBS treatment is a critical aspect for pharmaceutical manufacturers aiming to produce safe and effective medications. The consistent quality and well-established chemical synthesis of Clidinium Bromide solidify its position as a vital intermediate in the production of anticholinergic drugs, contributing significantly to patient care.